150 related articles for article (PubMed ID: 23512229)
21. The significance of dynamin 2 expression for prostate cancer progression, prognostication, and therapeutic targeting.
Xu B; Teng LH; Silva SD; Bijian K; Al Bashir S; Jie S; Dolph M; Alaoui-Jamali MA; Bismar TA
Cancer Med; 2014 Feb; 3(1):14-24. PubMed ID: 24402972
[TBL] [Abstract][Full Text] [Related]
22. Numerical aberrations of chromosomes 1 and 7 by fluorescent in situ hybridization and DNA ploidy analysis in breast cancer.
Kapranos N; Kounelis S; Karantasis H; Kouri E
Breast J; 2005; 11(6):448-53. PubMed ID: 16297090
[TBL] [Abstract][Full Text] [Related]
23. Prognostic value of Her-2/neu and DNA index for progression, metastasis and prostate cancer-specific death in men with long-term follow-up after radical prostatectomy.
Isharwal S; Miller MC; Epstein JI; Mangold LA; Humphreys E; Partin AW; Veltri RW
Int J Cancer; 2008 Dec; 123(11):2636-43. PubMed ID: 18767043
[TBL] [Abstract][Full Text] [Related]
24. Aneuploidy and aneusomy of chromosome 7 detected by fluorescence in situ hybridization are markers of poor prognosis in prostate cancer.
Alcaraz A; Takahashi S; Brown JA; Herath JF; Bergstralh EJ; Larson-Keller JJ; Lieber MM; Jenkins RB
Cancer Res; 1994 Aug; 54(15):3998-4002. PubMed ID: 7518348
[TBL] [Abstract][Full Text] [Related]
25. Prognostic significance of DNA ploidy in oral squamous cell carcinomas. A retrospective flow and image cytometric study with comparison of DNA ploidy in excisional biopsy specimens and resection specimens, primary, tumors, and lymph node metastases.
Baretton G; Li X; Stoll C; Fischer-Brandies E; Schmidt M; Löhrs U
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 1995 Jan; 79(1):68-76. PubMed ID: 7614165
[TBL] [Abstract][Full Text] [Related]
26. Aneuploidy of chromosome 9 and the tumor suppressor genes p16(INK4) and p15(INK4B) detected by in situ hybridization in locally advanced prostate cancer.
Heidenreich B; Heidenreich A; Sesterhenn A; Srivastava S; Moul JW; Sesterhenn IA
Eur Urol; 2000 Oct; 38(4):475-82. PubMed ID: 11025389
[TBL] [Abstract][Full Text] [Related]
27. ERG protein expression and genomic rearrangement status in primary and metastatic prostate cancer--a comparative study of two monoclonal antibodies.
Braun M; Goltz D; Adler D; Vogel W; Böhm D; Scheble V; Sotlar K; Fend F; Tan SH; Dobi A; Kristiansen G; Wernert N; Perner S
Prostate Cancer Prostatic Dis; 2012 Jun; 15(2):165-9. PubMed ID: 22231490
[TBL] [Abstract][Full Text] [Related]
28. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
29. Prevalence and prognostic significance of TMPRSS2-ERG gene fusion in lymph node positive prostate cancers.
Fleischmann A; Saramäki OR; Zlobec I; Rotzer D; Genitsch V; Seiler R; Visakorpi T; Thalmann GN
Prostate; 2014 Dec; 74(16):1647-54. PubMed ID: 25252136
[TBL] [Abstract][Full Text] [Related]
30. Prognostic factors in lymph node-positive prostate cancer.
Hofer MD; Kuefer R; Huang W; Li H; Bismar TA; Perner S; Hautmann RE; Sanda MG; Gschwend JE; Rubin MA
Urology; 2006 May; 67(5):1016-21. PubMed ID: 16698361
[TBL] [Abstract][Full Text] [Related]
31. Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization.
Qian J; Bostwick DG; Takahashi S; Borell TJ; Herath JF; Lieber MM; Jenkins RB
Cancer Res; 1995 Nov; 55(22):5408-14. PubMed ID: 7585610
[TBL] [Abstract][Full Text] [Related]
32. MiR-205 is progressively down-regulated in lymph node metastasis but fails as a prognostic biomarker in high-risk prostate cancer.
Kalogirou C; Spahn M; Krebs M; Joniau S; Lerut E; Burger M; Scholz CJ; Kneitz S; Riedmiller H; Kneitz B
Int J Mol Sci; 2013 Oct; 14(11):21414-34. PubMed ID: 24173237
[TBL] [Abstract][Full Text] [Related]
33. Deoxyribonucleic acid ploidy of core biopsies and metastatic lymph nodes of prostate cancer patients: impact on time to progression. The European Organization for Research and Treatment of Cancer Genitourinary Group.
van den Ouden D; Tribukait B; Blom JH; Fossa SD; Kurth KH; ten Kate FJ; Heiden T; Wang N; Schroder FH
J Urol; 1993 Aug; 150(2 Pt 1):400-6. PubMed ID: 8326563
[TBL] [Abstract][Full Text] [Related]
34. Pelvic lymph node dissection in prostate cancer.
Briganti A; Blute ML; Eastham JH; Graefen M; Heidenreich A; Karnes JR; Montorsi F; Studer UE
Eur Urol; 2009 Jun; 55(6):1251-65. PubMed ID: 19297079
[TBL] [Abstract][Full Text] [Related]
35. Numeric alterations in chromosomes 7 and 8 detected by fluorescent in situ hybridization correlate with high-grade localized prostate cancer.
Barranco MA; Alcaraz A; Corral JM; Solé M; Mallofré C; Llopis J; Rodríguez A; Ribal MJ; Alvarez-Vijande R; Carretero P
Eur Urol; 1998; 34(5):419-25. PubMed ID: 9803005
[TBL] [Abstract][Full Text] [Related]
36. Aneuploidy of chromosome Y in prostate tumors and seminal vesicles: a possible sign of aging rather than an indicator of carcinogenesis?
Nadal M; Pera G; Pujadas J; Abril J; González L; Aguiló F; Condom E; Gómez-Zaera M; Nunes V
Mol Carcinog; 2007 Jul; 46(7):543-52. PubMed ID: 17295237
[TBL] [Abstract][Full Text] [Related]
37. Research of the effect of miR-663 on the proliferation of prostate cancer cells, and the correlations of miR-663 with pathological grade and clinical stage.
Wang S; Liu J; Li C; Yang X
J BUON; 2017; 22(4):1011-1016. PubMed ID: 28952221
[TBL] [Abstract][Full Text] [Related]
38. p53 alteration in regional lymph node metastases from prostate carcinoma: a marker for progression?
Cheng L; Leibovich BC; Bergstralh EJ; Scherer BG; Pacelli A; Ramnani DM; Zincke H; Bostwick DG
Cancer; 1999 Jun; 85(11):2455-9. PubMed ID: 10357418
[TBL] [Abstract][Full Text] [Related]
39. KRAS and aneusomy of chromosomes 4, 10 and 12 in colorectal carcinomas.
Beyer K; Altendorf-Hofmann A; Chen Y; Bickel K; Petersen I
Pathol Res Pract; 2015 Sep; 211(9):646-51. PubMed ID: 26122820
[TBL] [Abstract][Full Text] [Related]
40. HOXB13 protein expression in metastatic lesions is a promising marker for prostate origin.
Varinot J; Furudoï A; Drouin S; Phe V; Penna RR; Roupret M; Bitker MO; Cussenot O; Compérat E
Virchows Arch; 2016 May; 468(5):619-22. PubMed ID: 26931741
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
